{"transactions":[{"id":389763,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":2,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":3,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T20:25:17.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":370000,"price":40.18,"value":14866600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All of the shares disposed of were sold by Pfizer Inc. (\"Pfizer\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 2,410,071 shares held of record by Pfizer Ventures (US) LLC, a controlled affiliate of Pfizer, 254,205 shares held of record by Pfizer, and 215,697 shares held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2879973,"source":{"system":"sec-edgar","filing":"0000078003-20-000038","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000038/primary_doc.xml","form_type":"4"}},{"id":403255,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":624205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":624205},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403254,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":215697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":215697},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403253,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":2360071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2360071},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403252,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":50000,"price":17,"value":850000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"PVUS purchased 50,000 additional shares of common stock in the Issuer's initial public offering for consideration of $17.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":3249973,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403251,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":624205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":3199973,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403250,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":215697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2575768,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403249,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":2360071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2360071,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}}]}